Patents by Inventor Tiziano Oldoni

Tiziano Oldoni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF HISTONE DEACETYLASE INHIBITORS FOR THE CARE OF PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE SYNDROMES
    Publication number: 20210128512
    Abstract: Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering therefrom by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 50 to 100 mg per patient.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 6, 2021
    Inventors: Tiziano OLDONI, Paolo MASCAGNI, Alessandro RAMBALDI, Tiziano BARBUI
  • USE OF HISTONE DEACETYLASE INHIBITORS FOR THE CARE OF PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE SYNDROMES
    Publication number: 20170049740
    Abstract: The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumour syndromes and may be from 10 to 150 mg/day/patient.
    Type: Application
    Filed: November 9, 2016
    Publication date: February 23, 2017
    Inventors: Tiziano OLDONI, Paolo MASCAGNI, Alessandro RAMBALDI, Tiziano BARBUI
  • Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
    Patent number: 9522127
    Abstract: Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering from such syndromes. The method is carried out by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl -methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 10 to 150 mg per patient.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: December 20, 2016
    Assignee: ITALFARMACO SPA
    Inventors: Tiziano Oldoni, Paolo Mascagni, Alessandro Rambaldi, Tiziano Barbui
  • Riluzole aqueous suspensions
    Patent number: 8765150
    Abstract: Physically and chemically stable aqueous oral suspensions of riluzole and manufacturing methods thereof. The suspensions contain riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is present in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 ?m. The suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: July 1, 2014
    Assignee: Italfarmaco SpA
    Inventors: Roberta Artico, Marco Adami, Daniele Barbareschi, Jaime Moscoso, Tiziano Oldoni, Paolo Mascagni
  • USE OF HISTONE DEACETYLASE INHIBITORS FOR THE CARE OF PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE SYNDROMES
    Publication number: 20140039059
    Abstract: The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumour syndromes and may be from 10 to 150 mg/day/patient.
    Type: Application
    Filed: October 7, 2013
    Publication date: February 6, 2014
    Applicant: ITALFARMACO SPA
    Inventors: Tiziano Oldoni, Paolo Mascagni, Alessandro Rambaldi, Tiziano Barbui
  • RILUZOLE AQUEOUS SUSPENSIONS
    Publication number: 20120039953
    Abstract: Physically and chemically stable aqueous suspensions of riluzole are disclosed together with the manufacturing methods thereof. Such aqueous suspensions comprise riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 ?m; such suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole.
    Type: Application
    Filed: March 2, 2010
    Publication date: February 16, 2012
    Applicant: Italfarmaco Spa
    Inventors: Roberta Artico, Marco Adami, Daniele Barbareschi, Jaime Moscoso, Tiziano Oldoni, Paolo Mascagni
  • Use of histone deacetylase inhibitors for the care of Philadephia-negative myeloproliferative syndromes
    Publication number: 20110294892
    Abstract: The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumor syndromes and may be from 10 to 150 mg/day/patient.
    Type: Application
    Filed: March 25, 2011
    Publication date: December 1, 2011
    Inventors: Tiziano Oldoni, Paolo Mascagni, Alessandro Rambaldi, Tiziano Barbui